Physician profile
Thomas D Ferro
NPI 1639118110
$28,495.97
in general payments reported to CMS, 2019-2025
10 companies · $5,899 in 2025
The $5,899 reported for 2025 was more than what 84% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $104 · 2021: $106 · 2022: $297 · 2023: $359 · 2024: $3,104 · 2025: $5,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $2,023 · Travel and Lodging: $1,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $2,023.29 |
| Travel and Lodging | $1,339.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corentec America INC | $25,742.10 | 2019-2025 | Corentec |
| Microport Orthopedics INC | $1,752.31 | 2019 | |
| Think Surgical, INC. | $282.63 | 2023 | |
| Cpm Medical Consultants, LLC | $203.98 | 2019 | |
| Nextstep Arthropedix, LLC | $170.35 | 2019-2021 | |
| Uoc USA INC | $160.08 | 2019-2022 | |
| Total Joint Orthopedics, INC. | $88.95 | 2025 | |
| Bioventus LLC | $37.37 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $30.50 | 2020 | |
| Pacira Therapeutics, INC. | $27.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ferro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.